Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression
2016; National Academy of Sciences; Volume: 113; Issue: 22 Linguagem: Inglês
10.1073/pnas.1600420113
ISSN1091-6490
AutoresKazumasa Komura, Seong Ho Jeong, Kunihiko Hinohara, Fangfang Qu, Xiaodong Wang, Masayuki Hiraki, Haruhito Azuma, Gwo‐Shu Mary Lee, Philip W. Kantoff, Christopher J. Sweeney,
Tópico(s)Hormonal and reproductive studies
ResumoSignificance The results of the recent clinical trials, ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) and Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE), suggest a significant contribution of androgen receptor signaling to sensitivity of docetaxel in prostate cancer. This study provides evidence that KDM5D (lysine-specific demethylase 5D) encoded on the Y chromosome plays an important role in docetaxel sensitivity by interacting with androgen receptor signaling, and that its expression level is associated with clinical outcomes. These data start to elucidate the biological underpinnings for the findings from these clinical trials.
Referência(s)